血脂康胶囊联合曲克芦丁治疗动脉粥样硬化血栓性脑梗死的临床研究

目的 探讨血脂康胶囊与曲克芦丁联合治疗动脉粥样硬化血栓性脑梗死的临床疗效。方法 选取2022年9月—2023年9月南阳市第二人民医院收治的100例动脉粥样硬化血栓性脑梗死患者，按随机数字表法将患者分对照组（50例）和治疗组（50例）。对照组患者静脉滴注曲克芦丁注射液，360 mg加入生理盐水150 mL,1次/d。在对照组的基础上，治疗组口服血脂康胶囊，2粒/次，2次/d。两组治疗14 d。观察两组患者临床疗效，比较治疗前后两组患者症状改善时间、日常生活能力量表评分指数（Barthel）、脑神经功能损伤程度量表（NIHSS）评分、及血清因子脂蛋白相关磷脂酶A2(LP-PLA2)、高迁移率族蛋白B1(HMGB1)、氧化低密度脂蛋白（ox-LDL）和血管间黏附分子-1(VCAM-1)水平。结果 治疗后，治疗组总有效率为98.00%，明显高于对照组总有效率（80.00%,P<0.05）。治疗后，治疗组肢体无力、肢体麻木感、头痛、眩晕等症状改善时间均明显短于对照组（P<0.05）。治疗后，两组Barthel指数评分明显升高，而NIHSS评分明显降低（P<0.05），且治疗组B...

Clinical study on Xuezhikang Capsules combined with troxerutin in treatment of atherosclerotic thrombotic cerebral infarction

Objective To explore the clinical effect of Xuezhikang Capsules combined with troxerutin in treatment of atherosclerotic thrombotic cerebral infarction. Methods Patients (100 cases) with atherosclerotic thrombotic cerebral infarction in Nanyang Second General Hospital from September 2022 to September 2023 were divided into control group (50 cases) and treatment group (50 cases) according to random number table method. Patients in the control group were iv administered with Troxerutin Injection, 360 mg added into normal saline 150 mL, once daily. Patients in the treatment group were po administered with Xuezhikang Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, Barthel and NIHSS scores, and the levels of LP-PLA2, HMGB1, ox-LDL, and VCAM-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.00%, which was significantly higher than that of the control group (80.005%, P < 0.05). After treatment, the improvement time of limb weakness, limb numbness, headache, dizziness and other symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the Barthel index score in two groups was significantly increased, while the NIHSS score was significantly decreased (P < 0.05), and the Barthel index and NIHSS score in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the serum levels of LP-PLA2, HMGB1, ox-LDL, and VCAM-1 in two groups were significantly decreased (P < 0.05), which in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The synergistic treatment of troxerutin and Xuezhikang Capsules can effectively improve the clinical symptoms, restore the injury of brain nerve function and improve the ability of daily life.